Global Glycomics/Glycobiology Market Size study & Forecast, by Product (Enzymes [Glycosidases, Transferases], Instruments [Mass Spectrometry, Chromatography, Arrays], Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End User and

The Global Glycomics/Glycobiology Market, currently valued at approximately USD 2.4 billion in 2024, is projected to expand at an impressive CAGR of 15.50% between 2025 and 2035, reaching USD 11.71 billion by the end of the forecast period. Glycomics—the comprehensive study of glycan structures, functions, and biology—has rapidly emerged as a transformative field in biotechnology, shaping advancements in diagnostics, drug discovery, and personalized medicine. The demand for glycomics solutions has surged in parallel with the growing understanding that glycans play a critical role in disease mechanisms, immune modulation, and therapeutic targeting. Increasing funding from public and private sectors, coupled with technological breakthroughs in analytical tools such as high-resolution mass spectrometry, advanced chromatography, and glycan arrays, is fueling adoption across pharmaceutical companies, research institutes, and diagnostic laboratories. Moreover, the integration of AI-driven bioinformatics into glycan analysis is accelerating biomarker identification and enhancing the precision of therapeutic development.

The market’s upward trajectory is also supported by a dramatic shift toward targeted biologics and biosimilars, where glycan characterization is vital for ensuring efficacy and safety. Expanding applications in oncology, infectious diseases, and autoimmune disorders are further driving demand for high-throughput glycomics platforms and reagent kits. According to industry reports, the increasing prevalence of chronic illnesses and the urgent need for novel therapeutics have prompted significant investments into glycoprotein research and structural glycomics. However, despite these promising growth catalysts, the field still faces bottlenecks such as the high cost of advanced analytical instruments, a shortage of skilled glycomics specialists, and the complexity of glycan data interpretation. Nevertheless, ongoing innovations in miniaturized assay systems, improved sample preparation techniques, and automated data processing promise to overcome these challenges, creating fertile ground for market expansion in the coming decade.

Regionally, North America currently leads the global glycomics/glycobiology market, driven by a robust biopharmaceutical industry, world-class research infrastructure, and sustained funding from institutions such as the NIH. The United States, in particular, is home to numerous companies at the forefront of glycan-based drug development and diagnostic innovation. Europe follows closely, propelled by strong academic-industry collaborations, government-backed research programs, and a growing focus on precision medicine initiatives. The Asia Pacific region is expected to witness the fastest growth through 2035, fueled by rapid expansion of life sciences research in countries like China, Japan, and India, coupled with increasing clinical trial activities and biomanufacturing investments. Latin America and the Middle East & Africa are also poised for gradual growth as they build research capacities, attract foreign investments, and integrate advanced glycomics platforms into regional healthcare systems.

Major market player included in this report are:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• New England Biolabs
• Shimadzu Corporation
• Waters Corporation
• Bruker Corporation
• Danaher Corporation
• PerkinElmer Inc.
• RayBiotech Life, Inc.
• Takara Bio Inc.
• Lectenz Bio
• Bio-Techne Corporation
• S-BIO (Sumitomo Bakelite Co., Ltd.)
• Z Biotech LLC

Global Glycomics/Glycobiology Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Enzymes (Glycosidases, Transferases)
• Instruments (Mass Spectrometry, Chromatography, Arrays)
• Kits
• Carbohydrates
• Reagents

By Application:
• Drug Discovery
• Diagnostics

By End User:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Diagnostic Laboratories

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more